Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis

Cardio-Oncology

Table 1 Characteristics of people with immune checkpoint inhibitor myocarditis with associated complete heart block

Age	Immune checkpoint inhibitor	Admission labs		Admission ECG			Treatment					Timeline Time (days) from first ICI to
Age	Immune checkpoint inhibitor	TnT	WBC	QRS (msec)	PR (msec)	SLI (mV)	IVIG	PLEX	TVP	Permanent device	Device lead complication*	Myocarditis	CHB	Death
83	Pembrolizumab	3409	19.2	136	**	12	-	-	-	-	-	24	24	26
79	Ipilimumab and Nivolumab	277	9.6	138	220	12	-	-	+	Leadless PPM	-	27	27	> 180
80	Nivolumab	620	6.7	134	182	11	-	-	+	Dual chamber PPM	-	28	28	121
79	Ipilimumab and Nivolumab	1162	13.9	124	166	5	+	-	+	-	-	25	26	33
58	Nivolumab	1169	10.3	130	204	3	+	-	+	Dual chamber PPM	A – lead dislodgement	22	22	44
70	Pembrolizumab	***	8.6	156	188	-	+	+	+	Dual chamber PPM	V—Failure to capture	19	21	> 180
81	Pembrolizumab	846	18	142	266	2	+	-	+	Dual chamber PPM	A – under-sensing	33	33	91

ICI immune checkpoint inhibitor, IVIG intravenous immunoglobulin, PLEX plasmapheresis, TVP transvenous pacemaker, PPM permanent pacemaker, WBC count white blood cell count. Time periods relate to days since first dose of ICI
^*A – atrial lead complication, V – ventricular lead complication
^**CHB present on admission
^***Troponin I was raised, TnT not performed

ISSN: 2057-3804